The Magnificent 7 could be in for a world of pain… And the insiders know it. It’s why Jeff Bezos just sold $3 billion of Amazon… it’s why Nvidia’s CEO just sold $713 million... and it’s why Zuckerberg just sold $1.3 billion in Meta stock. The financial establishment doesn’t want you to know about this… but a controversial new documentary just pulled back the curtain and exposed what’s really going on. It’s called The Final Frontier.

Click play to stream The Final Frontier at no cost

Robert E. Farrell, Jr. net worth and biography

Robert Farrell, Jr. Biography and Net Worth

CAO of Morphic

Robert E. Farrell Jr., CPA is the Senior Vice President of Finance/Operations and Chief Accounting Officer at Morphic Therapeutic Inc. and was part of the initial company formation in June 2015. Prior to joining Morphic Therapeutic, he served as Vice President of Finance and Administration and Treasurer of Genocea Biosciences from 2009 to 2015. Before that, he held senior level financial positions at Oscient Pharmaceuticals, Magen Biosciences and NeoGenesis Pharmaceuticals, Inc., where he directed companies through multiple private financings, acquisitions and several public offerings. Mr. Farrell is a licensed certified public accountant and holds a B.S. degree in accounting from Bentley University.

What is Robert E. Farrell, Jr.'s net worth?: The estimated net worth of Robert E. Farrell, Jr. is at least $785,379.19 as of July 8th, 2024. Mr. Farrell, Jr. owns 13,781 shares of Morphic stock worth more than $785,379 as of November 24th. This net worth estimate does not reflect any other investments that Mr. Farrell, Jr. may own. Learn More about Robert E. Farrell, Jr.'s net worth.
How do I contact Robert E. Farrell, Jr.?: The corporate mailing address for Mr. Farrell, Jr. and other Morphic executives is 35 Gatehouse Drive A2, Waltham MA, 02451. Morphic can also be reached via phone at (781) 996-0955. Learn More on Robert E. Farrell, Jr.'s contact information.
Has Robert E. Farrell, Jr. been buying or selling shares of Morphic?: Robert E. Farrell, Jr. has not been actively trading shares of Morphic during the last ninety days. Most recently, Robert E. Farrell, Jr. sold 30,272 shares of the business's stock in a transaction on Monday, July 8th. The shares were sold at an average price of $55.80, for a transaction totalling $1,689,177.60. Following the completion of the sale, the chief accounting officer now directly owns 13,781 shares of the company's stock, valued at $768,979.80. Learn More on Robert E. Farrell, Jr.'s trading history.
Who are Morphic's active insiders?: Morphic's insider roster includes Robert Farrell, Jr. (CAO), Peter Linde (Insider), Bruce Rogers (Insider), Marc Schegerin (CFO), and Timothy Springer (Director). Learn More on Morphic's active insiders.
Are insiders buying or selling shares of Morphic?: During the last twelve months, insiders at the sold shares 10 times. They sold a total of 161,666 shares worth more than $8,004,797.42. The most recent insider tranaction occured on July, 8th when President Bruce Rogers sold 20,000 shares worth more than $1,115,800.00. Insiders at Morphic own 25.6% of the company. Learn More about insider trades at Morphic.
Information on this page was last updated on 7/8/2024.

Robert E. Farrell, Jr. Insider Trading History at Morphic

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
7/8/2024	Sell	30,272	$55.80	$1,689,177.60	13,781
1/16/2024	Sell	5,089	$27.49	$139,896.61	34,992
5/23/2023	Sell	10,000	$60.00	$600,000.00	23,708
4/25/2023	Sell	10,000	$54.71	$547,100.00	12,222
4/20/2023	Sell	10,000	$45.00	$450,000.00	12,222
4/17/2023	Sell	20,000	$41.25	$825,000.00	2,222
1/14/2023	Sell	1,248	$30.63	$38,226.24	22,222
9/13/2021	Sell	3,049	$65.01	$198,215.49
9/10/2021	Sell	9,859	$65.14	$642,215.26	22,908
6/18/2021	Sell	200	$65.00	$13,000.00	18,234
6/16/2021	Sell	300	$65.00	$19,500.00	18,234
6/14/2021	Sell	3,526	$65.00	$229,190.00	33,934
6/10/2021	Sell	16,000	$60.08	$961,280.00	33,934
2/3/2021	Sell	25,000	$37.28	$932,000.00
12/30/2020	Sell	7,364	$32.56	$239,771.84	35,703
12/28/2020	Sell	12,636	$32.31	$408,269.16	35,703
11/9/2020	Sell	800	$28.00	$22,400.00	52,974
10/26/2020	Sell	1,760	$28.23	$49,684.80	55,534
10/23/2020	Sell	2,300	$28.31	$65,113.00	55,534
10/12/2020	Sell	1,149	$27.02	$31,045.98	59,083
10/8/2020	Sell	9,814	$26.24	$257,519.36	69,598
10/5/2020	Sell	2,000	$26.56	$53,120.00	74,655
10/1/2020	Sell	3,279	$27.61	$90,533.19	74,655
6/1/2020	Sell	6,681	$20.35	$135,958.35	84,615
5/29/2020	Sell	13,319	$20.17	$268,644.23	84,615

Robert E. Farrell, Jr. Buying and Selling Activity at Morphic

Morphic Company Overview

Morphic Holding, Inc., a biopharmaceutical company, discovers and develops oral small-molecule integrin therapeutics for the treatment of autoimmune, cardiovascular, and metabolic diseases, as well as fibrosis and cancer. Its lead product candidate MORF-057, an a4ß7-specific integrin inhibitor affecting inflammation is in Phase 2 clinical trials for the treatment of inflammatory bowel disease. The company's products in pipeline include Next Gen a4ß7 Inhibitors for additional potential GI indications, such as EGIDs, pouchitis, etc.; avß8 for the treatment of Myelofibrosis and solid tumor; and fibronectin integrin for pulmonary hypertensive. In addition, it has a license agreement with Janssen to discover and develop novel integrin therapeutics; collaboration agreement with Schrödinger for integrin targets; and license agreement with Children's Medical Center Corporation to develop and commercialize products worldwide for any therapeutic or diagnostic use in humans and veterinary applications. Morphic Holding, Inc. was incorporated in 2014 and is headquartered in Waltham, Massachusetts.

Today's Range

Now: $56.99

$56.99

50 Day Range

MA: $56.76

$55.74

$56.99

2 Week Range

Now: $56.99

$19.34

$57.00

Volume

400 shs

Average Volume

1,272,131 shs

Market Capitalization

$2.85 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.49

Nvidia’s world of pain awaits

From Porter & Company | Ad